Renal Failure Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031

The Global Renal Failure Treatment Market is projected to expand from USD 111.78 Billion in 2025 to USD 197.05 Billion by 2031, achieving a compound annual growth rate of 9.91%. This sector encompasses various therapeutic interventions and medical procedures, specifically kidney transplantation and dialysis, which are employed to manage acute or chronic renal function loss. The market's growth is fundamentally fueled by the increasing global prevalence of lifestyle-associated conditions, such as hypertension and diabetes, which are the leading causes of end-stage renal disease. Additionally, the rising geriatric demographic demands greater access to long-term renal replacement therapies, ensuring a steady demand for both peritoneal dialysis and hemodialysis modalities regardless of temporary market fluctuations.

However, the industry confronts a significant obstacle regarding the critical scarcity of donor organs, which severely curtails the volume of transplant surgeries and necessitates a dependence on expensive maintenance dialysis. This imbalance between supply and demand creates a major bottleneck in delivering definitive curative care. As reported by the National Kidney Foundation, there were 90,323 patients on the kidney transplant waiting list in the United States in 2024, highlighting the profound disparity between organ availability and the escalating number of patients requiring treatment.

Market Drivers

The rising global incidence of hypertension and diabetes serves as the primary catalyst for the renal failure treatment market, directly increasing the population requiring long-term care. As urbanization and sedentary lifestyles become more widespread, the prevalence of these chronic conditions accelerates the progression from Chronic Kidney Disease (CKD) to End-Stage Renal Disease (ESRD), requiring immediate therapeutic action. This continuous stream of patients is reflected in the operational metrics of major providers, underscoring the substantial demand for renal therapies. For instance, DaVita Inc. reported in their '4th Quarter 2024 Results' in February 2025 that they served approximately 281,100 dialysis patients, demonstrating the heavy burden on healthcare systems. Similarly, the scale of this demand is evident in the procedure volumes reported by Fresenius Medical Care, which performed around 48 million dialysis treatments globally in 2024.

Concurrently, the market is being reshaped by the increasing adoption of home-based dialysis modalities, driven by technological advancements and a clinical focus on improving patient quality of life. Innovations in remote monitoring systems and portable dialysis machines have made home treatment a practical and often preferred alternative to in-center care, offering patients greater independence and lower infection risks. Longitudinal data supports this structural shift toward flexible treatment options; according to the Medical Education Institute's January 2025 'Home Dialysis Updates from the 2024 USRDS Annual Data Report', the proportion of prevalent patients utilizing home hemodialysis grew by 60% during the analyzed period. Consequently, manufacturers are fast-tracking the development of user-friendly home hemodialysis and peritoneal solutions to capitalize on this expanding segment.

Market Challenges

The critical shortage of donor organs functions as a major restraint on the global renal failure treatment market by capping the volume of transplant procedures that can be performed. This scarcity limits the expansion of the surgical segment and restricts the uptake of post-transplant therapies, which are vital components of the market value chain. Because the supply of organs is inelastic compared to the rising incidence of renal disease, healthcare providers are unable to scale curative operations to meet patient needs. This physical limitation generates a bottleneck that prevents the market from fully capitalizing on the demand for permanent renal replacement solutions.

Consequently, the severe gap between supply and demand results in extended waiting periods that stall patient movement through the treatment ecosystem. Data from the United Network for Organ Sharing in 2024 revealed that only approximately 27,000 kidney transplants were performed in the United States during the preceding year, covering a small fraction of the total requirement. This limitation forces a continued dependence on maintenance dialysis, thereby hampering the growth of the transplant sector and stifling the potential for broader adoption of definitive curative treatments.

Market Trends

The expanded clinical application of GLP-1 agonists and SGLT2 inhibitors is fundamentally altering the treatment landscape by shifting focus from renal replacement to delaying disease progression. This trend is characterized by the widespread adoption of pharmaceutical interventions that mitigate the risk of adverse renal outcomes in patients with Type 2 diabetes and Chronic Kidney Disease (CKD). The market is seeing a surge in prescriptions for these therapies as clinical guidelines evolve to prioritize organ protection, effectively expanding the addressable market beyond traditional dialysis populations. This shift is substantiated by strong financial performance in the segment; according to Pharmaceutical Technology in August 2025, in the 'Novo Nordisk's diabetes and weight loss drug sales growth decelerates' article, sales for the company's diabetes and obesity care portfolio, which includes key renal-protective agents, grew 16% to DKK 145.4 billion in the first half of 2025.

Simultaneously, the integration of artificial intelligence for predictive renal analytics is transforming patient management through data-driven risk assessment and early intervention strategies. Healthcare providers are increasingly deploying AI-enabled diagnostic platforms to identify high-risk patients and optimize care pathways, thereby reducing the incidence of emergency dialysis starts. This technological adoption is being accelerated by improved reimbursement structures for digital diagnostic tools, which incentivizes clinical uptake. The growing commercial viability of these advanced analytics solutions is evident in recent financial disclosures; according to Renalytix PLC's March 2025 'Half Year Report', the company recorded that commercial insurance reimbursed testing revenue increased by 28% compared to the first half of the previous fiscal year, reflecting the rising utilization of prognostic testing in clinical practice.

Key Players Profiled in the Renal Failure Treatment Market

• NIPRO
• Fresenius Medical Care Holdings, Inc.
• Baxter International, Inc.
• Medtronic PLC
• B. Braun SE
• Asahi Kasei Medical Co., Ltd.
• AbbVie Inc.
• JMS Co.Ltd.
• Nikkiso Co., Ltd.
• AstraZeneca PLC

Report Scope

In this report, the Global Renal Failure Treatment Market has been segmented into the following categories:

Renal Failure Treatment Market, by Treatment:

• Dialysis
• Kidney Transplantation
• Drug Therapy
• Others

Renal Failure Treatment Market, by End Use:

• Hospitals
• Specialty Clinics
• Others

Renal Failure Treatment Market, by Region:

• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Renal Failure Treatment Market.

Available Customization

The analyst offers customization according to your specific needs. The following customization options are available for the report:

• Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.